Extensive genomic characterization of human cancers presents the problem of inference from genomic abnormalities to cancer phenotypes. To address this problem, we analysed proteomes of colon and rectal tumours characterized previously by The Cancer Genome Atlas (TCGA) and perform integrated proteogenomic analyses. Somatic variants displayed reduced protein abundance compared to germline variants. Messenger RNA transcript abundance did not reliably predict protein abundance differences between tumours. Proteomics identified five proteomic subtypes in the TCGA cohort, two of which overlapped with the TCGA 'microsatellite instability/CpG island methylation phenotype' transcriptomic subtype, but had distinct mutation, methylation and protein expression patterns associated with different clinical outcomes. Although copy number alterations showed strong cis-and trans-effects on mRNA abundance, relatively few of these extend to the protein level. Thus, proteomics data enabled prioritization of candidate driver genes. The chromosome 20q amplicon was associated with the largest global changes at both mRNA and protein levels; proteomics data highlighted potential 20q candidates, including HNF4A (hepatocyte nuclear factor 4, alpha), TOMM34 (translocase of outer mitochondrial membrane 34) and SRC (SRC proto-oncogene, non-receptor tyrosine kinase). Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
Extensive genomic characterization of human cancers presents the problem of inference from genomic abnormalities to cancer phenotypes. To address this problem, we analysed proteomes of colon and rectal tumours characterized previously by The Cancer Genome Atlas (TCGA) and perform integrated proteogenomic analyses. Somatic variants displayed reduced protein abundance compared to germline variants. Messenger RNA transcript abundance did not reliably predict protein abundance differences between tumours. Proteomics identified five proteomic subtypes in the TCGA cohort, two of which overlapped with the TCGA 'microsatellite instability/CpG island methylation phenotype' transcriptomic subtype, but had distinct mutation, methylation and protein expression patterns associated with different clinical outcomes. Although copy number alterations showed strong cis-and trans-effects on mRNA abundance, relatively few of these extend to the protein level. Thus, proteomics data enabled prioritization of candidate driver genes. The chromosome 20q amplicon was associated with the largest global changes at both mRNA and protein levels; proteomics data highlighted potential 20q candidates, including HNF4A (hepatocyte nuclear factor 4, alpha), TOMM34 (translocase of outer mitochondrial membrane 34) and SRC (SRC proto-oncogene, non-receptor tyrosine kinase). Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
TCGA has characterized the genomic features of human cancers [1] [2] [3] [4] [5] [6] and this has presented a new challenge of explaining how genomic alterations drive cancers 7 . As proteins link genotypes to phenotypes, the Clinical Proteomic Tumour Analysis Consortium (CPTAC) is performing proteomic analyses of TCGA tumour specimens for selected cancer types. Here we present the first integrated proteogenomic characterization of human cancer with an analysis of the TCGA colorectal cancer (CRC) specimens 6 . The TCGA study affirmed well-established genomic features of CRC and described three transcriptional subtypes, 17 chromosomal regions of significant focal amplification and 28 regions of significant focal deletion, and linked genomic features of CRC to critical signalling pathways. The drivers underlying copy number alterations (CNAs) and transcriptional subtypes are largely unknown, and an integrative analysis of both genomic and proteomic data may provide a more comprehensive understanding of the information flow from DNA to protein to phenotype.
Peptide and protein identification
We performed liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based shotgun proteomic analyses on 95 TCGA tumour samples (Extended Data Fig. 1 and Methods), the clinical and pathological characteristics and TCGA data sets for which are summarized in Supplementary Table 1 . Benchmark quality control samples from one basal and one luminal human breast tumour xenograft were analysed in alternating order after every five CRC samples (Methods).
We identified a total of 124,823 distinct peptides among the 95 samples, corresponding to 6,299,756 spectra in an assembly of 7,526 protein groups with a protein-level false discovery rate (FDR) of 2.64% (Methods and Extended Data Fig. 2 ). To facilitate integration between genomic and proteomic data, a gene-level assembly of the peptides identified 7,211 genes.
A fundamental question in proteogenomics is which protein coding alterations are expressed at the protein level. As standard database search approaches cannot identify variant peptides from MS/MS data, we also performed database searches with customized sequence databases from matched RNA sequencing (RNA-seq) data for individual samples 8, 9 (Methods and Extended Data Fig. 3) .
We identified 796 single amino acid variants (SAAVs) across all 86 tumours for which matched RNA-seq data were available (Fig. 1a, b and Supplementary Tables 2 and 3) , among which 64 corresponded to somatic variants reported by TCGA and 101 were reported in the COSMIC database (that is, COSMIC-supported variants). Of the remaining SAAVs, 526 were listed in the Single Nucleotide Polymorphism database (dbSNP) (that is, dbSNP-supported variants) and are likely to be germline variants. The 162 previously unreported SAAVs might be explained by novel somatic or germline variants, RNA editing, or, in some cases, false discovery.
The identified somatic variants were clearly enriched in the hypermutated samples, whereas the germline variants showed no association with hypermutation (Fig. 1a) . Although 58% of the germline variants occurred in two or more samples, almost all somatic variants occurred in only one sample (Fig. 1c) . The low identification rate for somatic variants may reflect relatively low sequence coverage in shotgun proteomics; however, somatic variants also might negatively impact protein abundance, possibly by reducing translational efficiency or protein stability 10 . Using the protein abundance quantification method described below and detailed in the Methods, we found that somatic variants exerted a significantly stronger negative impact on protein abundance than did dbSNP-supported variants (P , 2.2 3 10
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, Kolmogorov-Smirnov test; Fig. 1d and Methods). The percentage of variants with an impact score of less than 22 was doubled for somatic variants compared to dbSNPsupported variants (P , 2.2 3 10
, Chi-squared test; Fig. 1d ). Cancer-related variant proteins may serve as candidate protein biomarkers or therapeutic targets. The 108 somatic or COSMIC-supported protein variants mapped to 105 genes, including known cancer genes in the Cancer Gene Census database such as KRAS, CTNNB1, SF3B1, ALDH2 and FH. The list also included 14 targets of FDA-approved drugs or drugs in clinical trials 4 , such as ALDH2, HSD17B4, PARP1, P4HB, TST, GAK, SLC25A24 and SUPT16H. A subset of variant peptide sequences, including KRAS(Gly12Asp) were verified by targeted analyses of tumour lysates spiked with synthetic, isotope-labelled peptide standards (Methods). One example is shown in Extended Data Fig. 4 .
Quantification of protein abundance
To quantify protein abundance, we used spectral counts, which are the total number of MS/MS spectra acquired for peptides from a given protein 11 (Methods and Supplementary Table 4 ). Analysis of data from benchmark quality control samples demonstrated platform reproducibility throughout the analyses and enabled evaluation of data normalization methods (Extended Data Fig. 5a, b) . Based on the minimal spectral count requirement established using the quality control data set (Extended Data Fig. 5c ), 3,899 genes with a protein-level FDR of 0.43% were used to compare relative protein abundance across tumour samples.
mRNA versus protein abundance
The matched proteomic and RNA-seq measurements from the TCGA CRC tumours enabled the first global analysis of transcript-protein relationships in a large human tumour cohort (Methods). First, we compared the steady state mRNA and protein abundance for each gene within individual samples (Methods and Extended Data Fig. 6a ). All samples showed significant positive mRNA-protein correlation (multiple-test adjusted P , 0.01, Spearman's correlation coefficient) and the average correlation between steady state mRNA and protein abundance in individual samples was 0.47 ( Fig. 2a) , which is comparable to previous reports in multi-cellular organisms 12 . Next, we examined the concordance between mRNA and protein variation of individual genes across the 87 tumours for which 3,764 genes had both mRNA and protein measurements suitable for relative abundance comparison (Methods). Although 89% of the genes showed a positive mRNA-protein correlation, only 32% had statistically significant correlations (Fig. 2b) . The average Spearman's correlation between mRNA and protein variation was 0.23, which was comparable to reported values for yeast, mouse and human cell lines [13] [14] [15] . To test whether the concordance between protein and mRNA variation is related to the biological function of the gene product, we performed KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis (Methods and Supplementary Table 5) . Genes involved in several metabolic processes showed concordant mRNA and protein variation, whereas other gene classes showed low or even negative concordance in mRNA and protein variation (Fig. 2c) . We also found that genes with stable mRNA and stable protein tend to have higher mRNA-protein correlation than those with unstable mRNA and unstable protein (P 5 5.27 3 10
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, two-sided Wilcoxon rank-sum test, Methods, Extended Data  Fig. 6b) . Thus, mRNA measurements are poor predictors of protein abundance variations and both biological functions of the gene products and mRNA and protein stability may govern mRNA-protein correlation. 
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Impact of copy number alterations
The study by TCGA identified 17 regions of significant focal amplification and 28 regions of significant focal deletion. We examined the impact of CNAs on mRNA and protein abundance, including both cis-effects on the abundance of genes in the same loci and trans-effects on the abundance of genes at other loci in the genome (Methods). For all 23,125 genes with a CNA measurement in the TCGA data set, we calculated Spearman's correlation with mRNA and protein abundance, respectively for the 3,764 genes with both mRNA and protein measurements (Methods). Examination of the matrix visualizing significant CNAmRNA correlations (multiple-test adjusted P , 0.01) revealed strong positive correlations along the diagonal (Fig. 3a) , suggesting strong ciseffects of CNAs on mRNA abundance. Most of the diagonal signals corresponded to previously reported arm-level changes 6 . In contrast, the diagonal pattern was much weaker for CNA-protein correlations (Fig. 3b) .
To investigate further the cis-effects of CNAs, we separated all genes with CNA, mRNA and protein measurements into those in focal amplification regions, focal deletion regions and non-focal regions (that is, chromosomal regions without focal amplification or deletion). As shown in Extended Data Fig. 7 , CNA-mRNA correlations were significantly higher than CNA-protein correlations for genes in all three groups (P , 1.0 3 10
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, Kolmogorov-Smirnov test). Moreover, genes in the focal amplification regions showed significantly higher CNA-mRNA and CNA-protein correlations than genes in the non-focal regions (P 5 4.4 3 10 24 and 0.02, respectively, Kolmogorov-Smirnov test). However, the same trend was not observed for genes in the focal deletion regions. Therefore, focal amplifications have the strongest cis-effects on both mRNA and protein abundance, suggesting that selection for high protein abundance may drive CNA in regions of focal amplification. However, many CNA-driven mRNA level increases do not translate into increased abundance of the corresponding proteins. Figure 3a , b also revealed multiple trans-acting CNA hot spots, defined as chromosomal loci whose alteration is significantly associated with abundance changes of many transcripts or proteins at other loci. Chromosomes 20q, 18, 16, 13 and 7 contained the five strongest hot spots driving global mRNA abundance variation. These hot spots also were strongest at the protein level. Most hot-spot-related transcript changes did not propagate to the protein level, presumably reflecting buffering of protein abundance by post-transcriptional regulation 16, 17 . Notably, many hot-spot-associated protein-level alterations occurred in the absence of corresponding mRNA alterations, suggesting that the same trans-acting hot spot may exert independent effects at both the transcriptome and proteome levels.
The 20q amplification was associated with the largest global changes in both mRNA and protein levels in this univariate analysis. The same conclusion was reached with a regularized multivariate regression analysis method, remMap 18 (Methods and Supplementary Tables 6-9 ). These The top panels show copy-number-abundance correlation matrices for mRNA abundance (a) and protein abundance (b) with significant positive and negative correlations (multiple-test adjusted P , 0.01, Spearman's correlation coefficient) indicated by red and green, respectively, and genes ordered by chromosomal location on both x and y axes. The bottom panels show the frequency of mRNAs and proteins associated with a particular copy number alteration, where blue and black bars represent associations specific to mRNA and protein or common to both mRNA and protein, respectively. c-e, HNF4A (c), TOMM34 (d) and SRC (e) showed significant CNA-mRNA, mRNA-protein, and CNA-protein correlations (Spearman's correlation coefficient). The colour grade from light yellow to red indicates relatively low-level (yellow) to high-level (red) of copy number, mRNA abundance, or relative protein abundance among the 85 samples, which were ordered by copy number data.
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data highlight the importance of 20q amplification in CRC, which has not been well documented in previous studies. Among the 79 genes in the 20q region with quantifiable protein measurements, 67 (85%) showed significant CNA-mRNA correlation, but only 40 (51%) showed significant CNA-protein correlation (multiple-test adjusted P , 0.01, Spearman's correlation coefficient, Supplementary Table 10) . As significant CNA-protein correlations identify amplified sequences that translate to high protein abundance, proteomic measurements can help prioritize genes in amplified regions for further examination. Of particular interest among the 40 genes is HNF4A (Fig. 3c) , a candidate driver gene nominated by TCGA for the 20q13.12 focal amplification peak 6 . HNF4a is a transcription factor with a key role in normal gastrointestinal development 19 and is increasingly being linked to CRC 20 . However, there are contradictory reports on whether HNF4a acts as an oncogene or a tumour suppressor gene in CRC 20 . Upon reanalysis of the HNF4A short hairpin RNA (shRNA) knockdown data for CRC cell lines from the Achilles project 21 , we found that the dependency of CRC cells on HNF4a correlated significantly with the amplification level of HNF4A (Methods and Extended Data Fig. 8 ), which may partially explain the contradictory roles reported for HNF4a in CRC. Other interesting candidates included TOMM34 (Fig. 3d) , which is overexpressed frequently in CRC tumours and is involved in the growth of CRC cells 22 , and SRC (Fig. 3e) , which encodes a non-receptor tyrosine kinase implicated in several human cancers including CRC 23 .
Proteomic subtypes of CRC
The TCGA study reported three transcriptomic subtypes of CRC, designated 'microsatellite instability/CpG island methylator phenotype' (MSI/ CIMP), 'invasive', and 'chromosomal instability' (CIN). Given the limited correlation between mRNA and protein levels, we asked whether CRC subtypes can be better represented with proteomics data. Using the consensus clustering 24 method (Methods and Extended Data Fig. 9 ), we identified five major proteomic subtypes in this tumour cohort, with 15, 9, 25, 11 and 19 cases in subtypes A to E, respectively (Fig. 4a) .
We tested the association between the subtype classification and established genomic and epigenomic features of CRC using Fisher's exact test (Fig. 4b and Supplementary Table 11 ). Almost all hypermutated and MSI-high tumours were included in subtypes B and C, as well as tumours with POLE and BRAF mutations. However, statistically significant association with these features was only observed for subtype B (multipletest adjusted P , 0.05). Moreover, subtype B was significantly associated with the TCGA CIMP -high methylation subtype, whereas subtype C was significantly associated with a non-CIMP subtype (cluster 4). Another unique feature of subtype B was the lack of TP53 mutations and chromosome 18q loss. These results clearly established the association between proteomic subtype B and MSI-high and CIMP, but suggest that subtype C may have different biological underpinnings.
The remaining three subtypes were associated with CIN, another well-accepted genetic property of CRC. In particular, subtype E was significantly associated with both TP53 mutations and 18q loss, genomic features frequently associated with CIN tumours 25 . Interestingly, subtype E was also associated with HNF4A amplification and relatively higher abundance of HNF4a protein (Fig. 4c ). HNF4a abundance was significantly higher in subtype E tumours compared to normal colon samples (multiple-test adjusted P 5 1.09 3 10
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, two-sided Wilcoxon rank-sum test); however, significant upregulation of HNF4a was not observed for other subtypes (Methods). This result, together with our reanalysis of shRNA knockdown data from the Achilles project (Extended Data Fig. 8 ), suggests that HNF4a dependency may be particularly associated with the subset of tumours or cells with HNF4A amplification. b, Association of proteomic subtypes with major colorectal-cancer-associated genomic alterations and previously published transcriptomic and methylation subtypes. Subtypes that are significantly overlapped with a transcriptomic or methylation subtype are highlighted by pink boxes. Both proteomic subtypes B and C showed significant overlap with the TCGA MSI/CIMP subtype. In addition, they showed significant overlap with the CCS2 and CCS3 subtypes in the ref. 26 classification, respectively. Proteomic subtype B significantly overlapped with the TCGA CIMP-high methylation subtype, whereas subtype C significantly overlapped with a non-methylation subtype (TCGA cluster 4 methylation subtype). Subtypes overrepresented with a specific genomic alteration are also highlighted by pink boxes. The green box highlights the absence of TP53 mutations and 18q loss in subtype B. c, The top panel shows HNF4A copy number and relative abundance of HNF4a protein in the five subtypes; the bottom panel compares relative abundance of HNF4a in the five subtypes to that in normal colon samples, respectively, and the adjusted P values are based on the two-sided Wilcoxon rank-sum test followed by multiple-test adjustment.
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We also examined the association between the subtype classification and clinical features and found only that stage II tumours were significantly enriched in subtype C (multiple-test adjusted P , 0.05; Supplementary Table 11 ). Supervised statistical analyses at the individual protein level for 13 clinical and genomic features also identified few, if any, significant protein effects of these features, except for hypermutation status, MSI status and 18q loss (Supplementary Table 12 ), suggesting that the proteomic subtypes identified by the unsupervised clustering analysis captured the major proteome variations across the tumours.
Next, we compared the proteomic subtype classification with the TCGA transcriptional subtype classification for the 62 samples that had both subtype labels. Proteomic subtypes B and C both showed significant association with the TCGA subtype MSI/CIMP ( Fig. 4b and Supplementary Table 11 ); however, they differ considerably at genomic, epigenomic and proteomic levels (Fig. 4a, b) . We also examined alternative classifications of the TCGA samples based on two recently published transcriptomic subtype classifiers 26, 27 . Proteomic subtype C, but not subtype B, showed enriched overlap with the 'stem-like' subtype described in ref. 27 and the colon cancer subtype 3 (CCS3) subtype described in ref. 26 . Interestingly, tumours with stem-like and CCS3 classifications both have poor prognosis, which suggests that proteome subtype C also may be associated with poor prognosis. Therefore, the ability to distinguish subtype B from C through proteomics data are important, because MSI-high tumours typically have better prognosis 25 .
Signatures for proteomic subtypes
To better understand the biology underlying the proteomic subtypes, we identified protein signatures for each subtype by supervised comparison of protein abundance in that subtype against all others; we also required signature proteins for a subtype to be significantly different in abundance compared to normal colon samples from 30 individuals analysed on the same proteome analysis platform (Methods and Supplementary  Tables 13 and 14) . As shown in Extended Data Fig. 10a , all CRC subtypes displayed more than 2,000 (.60%) significant protein abundance differences compared to normal colon. Although a full validation of the proteomic subtypes and protein signatures for the subtypes will require proteomic profiling data from an independent tumour cohort, a low cross-validation error rate of 3.8% demonstrated good generalizability of the subtypes and their signature proteins (Methods).
We performed Gene Ontology enrichment analysis for the subtype signatures using WebGestalt 28 (Methods and Supplementary Table 15) . Genes involved in 'response to wounding' were significantly enriched in the up-signature of subtype C (multiple-test adjusted P , 2.2 3 10 216 , Fisher's exact test). The wound-response gene signature is a powerful predictor of poor clinical outcome in patients with early stage breast cancers 29 . This result further links our subtype C to poor prognosis. To understand better the functional networks underlying this subtype with potential clinical importance, we uploaded the up and down signatures of subtype C to NetGestalt 30 for enriched protein-protein interaction network module analysis. Four network modules were enriched with genes in the up signature for subtype C, whereas two modules were enriched with genes in the down signature (multiple-test adjusted P , 0.01, Fisher's exact test; Extended Data Fig. 10b) . Notably, the downsignature-enriched module (III) included the E-cadherin (CDH1)-bcatenin (CTNNB1)-a-catenin (CTNNA1) complex (Extended Data Fig. 10c , e). E-cadherin, the most under-expressed protein in the subnetwork, suppresses invasion in lobular breast carcinoma 31 and is a switch for the epithelial-to-mesenchymal transition (EMT), which is associated with poor prognosis in colon cancer 32 . Other components of the module were desmosomal proteins (PKP2, JUP and DSG2) and cytokeratins (KRT18, KRT6A and KRT8). Reduction in both desmosome formation and cytokeratin expression is associated with EMT 33 . Moreover, proteins in the most significantly upregulated network module (Extended Data Fig. 10d, f) included collagens (COL1A1 and COL3A1) and extracellular matrix glycoproteins (FN1, BGN, FBN1 and FBN2) that also are markers of EMT 34, 35 . These data strengthen the association of subtype C with poor prognosis and relate it to EMT activation.
Discussion
Our proteomic characterization of the genomically annotated TCGA colon tumours illustrates the power of integrated proteogenomic analysis. The data demonstrate that protein abundance cannot be reliably predicted from DNA-or RNA-level measurements. mRNA and protein levels were modestly correlated, as earlier cell and animal model studies suggested 36 , but over two-thirds of these correlations were not statistically significant in the TCGA tumour set. Although most CNAs in CRC drive mRNA abundance changes, relatively few translated to consistent changes in protein abundance.
Genomic and proteomic technologies provide reinforcing data. RNAseq data facilitate the discovery of variant proteins, which could serve as possible biomarker candidates or therapeutic targets. Combined mRNA and protein profiling data can identify potentially relevant genes in amplified chromosomal regions. This approach, which revealed the importance of chromosome 20q amplification and provided new insights into the role of HNF4a in CRC, can be broadly extended to understand roles of CNAs in other cancers. Proteomics identified CRC subtypes similar to those detectable by transcriptome profiles, but further captured features not detectable in transcript profiles. The separation of the TCGA MSI/CIMP subtype into distinct proteotypes illustrates the unique potential of proteomics-based subtyping. After validation in independent cohorts, protein subtype signatures could be directly translated into laboratory tests for tumour classification. Integrated proteogenomic analysis, as demonstrated in this study, will enable new advances in cancer biology, diagnostics and therapeutics.
METHODS SUMMARY
All tumour samples for the current study were obtained through the TCGA Biospecimen Core Resource (BCR) as described previously 6 . No other selection criteria other than availability were applied for this study. Patient-derived xenograft tumours from established basal and luminal B breast cancer intrinsic subtypes 37, 38 were raised subcutaneously in 8-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (Jackson Laboratories, Bar Harbour, Maine) as described previously 39, 40 . Normal colon biopsies were obtained from screening colonoscopies performed between July 2006 and October 2010 under Vanderbilt University Institutional Review Board (IRB) approval no. 061096.
Tissue proteins were extracted and tryptic peptide digests were analysed by multidimensional liquid chromatography-tandem mass spectrometry. Xenograft quality control samples were run after every five colorectal tumour samples. Raw data were processed for peptide identification by database and spectral library searching and identified peptides were assembled as proteins and mapped to gene identifiers for proteogenomic comparisons. Quantitative proteomic comparisons were based on spectral count data. Detailed descriptions of the samples, LC-MS/ MS analysis, and data analysis methods can be found in the Methods. All of the primary mass spectrometry data on TCGA tumour samples are deposited at the CPTAC Data Coordinating Center as raw and mzML files and complete protein assembly data sets for public access (https://cptac-data-portal.georgetown.edu).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
TCGA tumour samples. All samples for the current study were obtained through the TCGA Biospecimen Core Resource (BCR) as described previously 6 . Of the 276 samples described in the TCGA study, 95 specimens from 90 patients were available for the current study (Supplementary Table 1) . No other selection criteria other than availability were applied for this study. Specimens for proteomic study were sectioned sequentially from the tumour blocks used for genomic studies, hence the 'bottom' slides from the genomic studies are representative of the material used for proteomics. The slides are available from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). All samples contained at least 60% tumour nuclei, as described earlier 6 . Samples were shipped from the TCGA BCR in dry ice and kept frozen at 280 uC until processing. All TCGA colorectal tissue samples were washed before digestion to eliminate any residual optimal cutting temperature compound (OCT) 37, 38 were raised subcutaneously in 8-week-old NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ mice (Jackson Laboratories, Bar Harbour, Maine) as described previously 39, 40 . These tumours have significantly different gene expression and proteomic signatures 40 that are related to their intrinsic biology and endocrine signalling. Tumours from each animal were collected by surgical excision at approximately 1.5 cm 3 with minimal ischaemia time by immediate immersion in a liquid nitrogen bath. The tumour tissues were then placed in pre-cooled tubes on dry ice and stored at 280 uC. A tissue 'pool' of cryopulverized tumours was prepared in order to generate sufficient material that could be reliably shared and analysed between multiple laboratories.
In brief, tumour pieces were transferred into pre-cooled Covaris Tissue-Tube 1 Extra (TT01xt) bags (Covaris no. 520007) and processed in a Covaris CP02 Cryoprep device using different impact settings according to the total tumour tissue weight: ,250 mg 5 3; 250-350 mg 5 4; 350-440 mg 5 5; 440-550 mg 5 6. Tissue powder was transferred to an aluminium weighing dish (VWR no. 1131-436) on dry ice and the tissue was thoroughly mixed with a metal spatula precooled in liquid nitrogen. The tissue powder was then partitioned (,100-mg aliquots) into precooled cryovials (Corning no. 430487). All procedures were carried out on dry ice to maintain tissue in a powdered, frozen state. Protein extraction and peptide fractionation. Protein extraction and digestion of tissue specimens. Following OCT removal, tissue specimens were placed in 1.5-ml micro-centrifuge tubes and re-suspended in 100 ml of trifluoroethanol (TFE) and 100 ml of 100 mM ammonium bicarbonate, pH 8.0. If additional buffer was required, equal volumes of TFE and 100 mM ammonium bicarbonate pH 8.0, were added accordingly. In addition, powderized xenograft tumour tissue representing the comparison and reference (CompRef) samples for luminal (WHIM16) and basal (WHIM2) breast cancer subtypes were analysed with each set of 10 TCGA colorectal tissue samples. Samples were sonicated using a Fisher Scientific Sonic Dismembrator Model 100 at a setting of 20 W for 20 s followed by 30 s incubation on ice. This sonication step was repeated twice and samples were placed on ice between sonications. The resulting homogenate was heated with shaking at 1000 r.p.m. for 1 h at 60 uC followed by a second series of sonication steps, as described above. A protein measurement then was obtained for each sample using the BCA Protein Assay (ThermoFisher Pierce, Rockford, Illinois) using the manufacturer's protocol.
An aliquot equivalent to 200 mg was removed and reduced with tris(2-carboxyethyl)phosphine (TCEP, 20 mM) and dithiothreitol (DTT, 50 mM) at 60 uC for 30 min followed by alkylation with iodoacetamide (IAM, 100 mM) in the dark at room temperature for 20 min. The lysate was diluted with the appropriate volume of 50 mM ammonium bicarbonate, pH 8.0, to reduce the TFE concentration to 10%, trypsin was added at a ratio of 1:50 (w:w) and digested overnight at 37 uC. The digested mixture was frozen at280 uC and lyophilized to dryness. The lyophilized samples were re-suspended in 350 ml of high-pressure liquid chromatography (HPLC)-grade water and vortexed vigorously for 1 min and desalted using an Oasis HLB 96-well mElution plate (30 mm, 5 mg, Waters Corp., Milford, Massachusetts), which was pre-washed with 500 ml of acetonitrile and equilibrated with 750 ml of HPLC-grade water. The flow-through was discarded and the plates were washed with 500 ml of HPLC-grade water and the peptides eluted with 80% acetonitrile and the eluates were evaporated to dryness in vacuo. Samples were stored in the freezer until further analysis. Peptide fractionation by basic reverse-phase liquid chromatography. Samples were reconstituted in 300 ml of solvent A (1.0 M triethylamine bicarbonate (TEAB), pH 7.5). The reconstituted sample was then diluted with an additional 100 ml of solvent A and the entire 400 ml of solution was injected into the basic reversephase liquid chromatography (basic RPLC) column. Tryptic peptides were fractionated using high-pH RPLC separation with an XBridge BEH C18, 250 mm 3 4.6 mm analytical column (130A, 5 mm particle size) equipped with a XBridge BEH C18 Sentry guard cartridge at a flow rate of 0.5 ml min
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. The solvents were 10 mM TEAB, pH 7.5, in water as mobile phase A and 100% acetonitrile as mobile phase B. Sample fractionation was accomplished using the following multistep linear gradient: from 0 to 5% B in 10 min, from 5 to 35% B in 60 min, from 35-70% in 15 min and held at 70% B for an additional 10 min before returning to initial conditions. A total of 60 fractions were collected over the 105-min gradient and concatenated into 15 fractions by combining fractions 1, 16, 31, 46; 2, 17, 32, 47; and so on up to fractions 15, 30, 45 and 60. The samples were evaporated to dryness in a Speed-Vac sample concentrator and stored at 280 uC until LC-MS/ MS analysis. LC-MS/MS analysis. Resulting peptide fractions were resuspended in 50 ml of water containing 2% acetonitrile and 0.1% formic acid and analysed using a Thermo LTQ Orbitrap Velos ion trap mass spectrometer equipped with an Eksigent NanoLC 2D pump and AS-1 autosampler. A 2-ml injection volume of the peptide solution was separated on a packed capillary tip (Polymicro Technologies, 100 mm 3 11 cm) containing Jupiter C18 resin (5 mm, 300 Å , Phenomenex) using an in-line solid-phase extraction column (100 mm 3 6 cm) packed with the same C18 resin using a frit generated with liquid silicate Kasil 41 . Mobile phase A consisted of 0.1% formic acid and Mobile phase B consisted of 0.1% formic acid in acetonitrile. A 95-min gradient was preceded by a 15-min washing period (100% A) at a flow rate of 1.5 ml min 21 to remove residual salt. Following the wash, the mobile phase was programmed to 25% B by 50 min, followed by an increase to 90% B by 65 min and held for 9 min before returning to the initial conditions. A full MS scan was collected for peptides from 400-2,000 m/z on the Orbitrap at a resolution of 60,000 followed by eight data-dependent MS/MS scans from lowest to highest signal intensity on the linear trap quadrupole (LTQ). Centroided MS/MS scans were acquired using an isolation width of 3 m/z, an activation time of 30 ms, an activation q of 0.250 and 35% normalized collision energy. One microscan with a max ion time of 100 ms and 1,000 ms was used for each MS/MS and full MS scan, respectively. MS/MS spectra were collected using a dynamic exclusion of 60 s with a repeat of 1 and repeat duration of 1.
All TCGA samples were analysed on the same Thermo LTQ Orbitrap Velos instrument, with sample analysis beginning on 26 July 2012 and concluding on 17 February 2013. Benchmark quality control samples from one basal and one luminal human breast tumour xenograft were analysed in alternating order after every five CRC samples. Specifically, five TCGA samples were run on the instrument, followed by a luminal CompRef sample, and then another five TCGA samples followed by a basal CompRef sample. Bovine serum albumin (BSA) tryptic digest standards were analysed before and after every ten TCGA samples and were used to monitor instrument sensitivity, BSA standard sequence coverage and chromatographic performance to determine acceptance or rejection of the acquired data. LC-MS/MS data analysis. Peptide identification. Basic protein identification used the RefSeq human protein sequence database, release version 54, and both database and peptide library search strategies. Two bovine trypsin sequences and one porcine trypsin sequence were appended to these 34,586 sequences. The 14 June 2011 National Institute of Standards and Technology (NIST) human spectral library for ion traps (617,000 spectra, counting paired decoys) was indexed against this sequence database. Thermo RAW files were converted to mzML peaklists by the ScanSifter algorithm 42 or by ProteoWizard msConvert 43 . The ScanSifter files were employed by Pepitome 1.0.42 (ref. 44 ) for spectral library search and MyriMatch 2.1.87 (ref. 45 ) for database search, whereas the msConvert files were used by MS-GF1 v9176 (ref. 46 ). Pepitome and MyriMatch used precursor tolerances of 10 p.p.m., while MS-GF1 used a 20-p.p.m. window; all three algorithms allowed fragments to vary by up to 0.5 m/z, and both database search engines considered semi-tryptic peptides equally with fully tryptic peptides, allowed for isotopic error in precursor ion selection, conducted on-the-fly peptide sequence reversal, and applied static 157 modifications to cysteines and dynamic 116 oxidations to methionines. MS-GF1 considered acetylation for protein amino termini, whereas MyriMatch added pyroglutamine modifications to the N termini of peptides starting with Gln residues. Pepitome considered any modification variants and trypsin specificities that were included in the spectral library.
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Protein assembly. Spectral identification files from each of the search engines (pepXML for Myrimatch and Pepitome, mzIdent for MS-GF1) were converted to IDPicker 3 index files (idpXML) using IDPicker 3 (ref. 47 ). The resulting 4,275 idpXML files (95 samples 3 15 fractions 3 3 search engines) were used for a final protein assembly using IDPicker 3. For initial protein assembly, peptide identification stringency was set at a maximum of 1% reversed peptide matches, that is, 2% peptide-to-spectrum matches (PSM) FDR and a minimum of 2 unique peptides to identify a given protein within the full data set. Because the majority of false identifications occur with low frequency, the number of proteins identified by reversed peptides (false-positive protein identifications) expands exponentially with the size of the data set. In this case, a 2% PSM FDR resulted in an unacceptably high 32% FDR at the protein level. To maximize both the number of proteins identified as well as the number of spectra observed for each protein, we adopted a procedure similar to that outlined in ref. 48 . To optimize the number of proteins identified we applied a very stringent filter at 0.1% PSM FDR and a minimum of 2 distinct peptides identified for each protein. This filter resulted in the identification of a total of 94,442 distinct peptides among the 95 samples representing 7,526 protein groups with a protein-level FDR of 2.64%. To rescue high quality PSMs that were excluded by the stringent PSM FDR threshold, we relaxed the PSM FDR threshold to 1% for the confidently identified proteins. This process increased the number of distinct peptides identified to 124,823, corresponding to a total number of 6,299,756 spectra; the rescued PSMs were of high quality, with a median PSM FDR of less than 0.2% (Extended Data Fig. 2) , indicating the maintained integrity of the data set. To facilitate the integration between genomic and proteomic data, we further assembled the peptides at the gene level. This assembly resulted in 7,211 gene groups with a gene-level FDR of 2.7%. Genes identified from each sample ranged from 3,372 to 5,456, with a median gene count of 4,656 for the 95 samples. 1,530 genes (21%) were found in all 95 samples, 4,628 genes (64%) in more than half of the samples, and only 10 genes (0.1%) in just a single sample. Variant peptide identification. To identify variant peptides, we used a customized protein sequence database approach 9 , in which we derived customized protein sequence databases from matched RNA-seq data and then performed database searches using the customized databases for individual samples.
To identify SNVs and indels from RNA-seq data, BAM files for 86 of the 90 patients were downloaded from CGHub in February 2013. Although 87 samples were analysed by RNA-seq, we were unable to obtain the bam file for one of the 87 samples. Tophat (v2.0.7) was used to re-align reads to human reference genome (hg19) in a spliced mode using default parameters, allowing a maximum of 10 hits per read. The resulting BAM files were indexed using samtools (0.1.18, http:// samtools.sourceforge.net/). We used a custom-written script to summarize the reads mapping information (Extended Data Fig. 3a) and calculate the exon coverage. As shown in Extended Data Fig. 3b , 76% of exons were covered by RNAseq reads, and 64% had an average coverage greater than 1.
Putative SNVs and short indels were called one library at a time using mpileup from samtools and varFilter. Putative SNVs were further filtered based on the following criteria: SNP quality $ 20; mapping quality $ 20; and read depth $ 3 and then recorded in a variant call format (VCF) file. For short INDEL candidates, gapped reads $ 3 were required.
For customized database construction and variant peptide identification we used an R package customProDB 8 (http://bioconductor.org/packages/2.13/bioc/ html/customProDB.html) to annotate variations predicted from RNA-seq, including mapping to dbSNP135 and COSMIC64 databases. For each sample, customProDB generates a protein FASTA database by appending proteins with nonsynonymous protein coding SNVs and aberrant proteins to the end of the standard RefSeq human protein sequence database. Owing to the low coverage of this RNA-seq data set, we did not remove the low abundance transcripts from the standard RefSeq database. Peptide identification was performed for each sample separately using corresponding customized FASTA database and MyriMatch 2.1.87 (ref. 45) . Search settings were identical to those described for Myrimatch above. IDPicker 3 was used for protein assembly as described earlier, except that the data set was filtered at 1% PSM FDR and a minimum of 5 spectra identified per protein. The full data set consisted of 8,352 protein groups with 1.8% protein FDR. Identified SAAVs were further annotated for existence in the somatic variant list published by TCGA 6 (that is, TCGA-somatic variants), existence in the COSMIC64 database (that is, COSMICsupported variants), and existence in the dbSNP135 database (that is, dbSNP-supported variants). To identify TCGA-somatic variants, we downloaded the MAF (mutation annotation format) files from the Firehose website (http://gdac.broadinstitute.org, version 20130523). As the coordinates in MAF files were based on hg18, liftOver (http://hgdownload.cse.ucsc.edu/admin/exe/) from UCSC was used to convert genome coordinates to hg19. Support of these somatic mutations by RNA-seq data are shown in Extended Data Fig. 3c . All identified variant peptides as well as SAAVs and their annotations can be found in Supplementary Tables 2 and 3 .
Protein quantification. We used spectral count, or the total number of MS/MS spectra taken on peptides from a given protein in a given LC/LC2MS/MS analysis as the basis for protein quantification. Spectral count is linearly correlated with the protein abundance over a large dynamic range 11 . This simple but practical quantification method has found broad application in detecting differential or correlated protein expression [49] [50] [51] [52] [53] , and multiple groups have concluded that spectral counting achieves similar accuracy to more complex methods such as the intensity-based techniques [53] [54] [55] . Previously, we have confirmed proteomic changes detected from spectral count data by targeted proteomics with multiple reaction monitoring (MRM) in different data sets 56, 57 . For the quality control sample data set, spectral count data were summarized at the protein group level, where a protein group is defined as the set of proteins that are indiscernible on the basis of the observed peptides. For each group, a random protein was selected to represent the group. The final spectral count table has data for 7,440 proteins and 20 samples, with 10 basal samples and 10 luminal samples.
For the TCGA tumour data set, to facilitate the integration between genomic and proteomic data, spectral count data were summarized at the gene group level, where a gene group is defined as the set of genes that are indiscernible on the basis of the observed peptides. To ensure reproducibility, for each gene, the longest protein was selected for the calculation of protein length. For each gene group, the gene with the shortest protein length was selected to represent the group following the Occam's razor principle. The final spectral count table has data for 7,211 genes and 95 samples (5 tumours have duplicated samples; Supplementary Table  4) . For analysis that required only one sample from the duplicates, the sample with a larger total spectral count was selected.
For platform evaluation, we used the quality control data set to evaluate the technical variability in both protein identification and quantification based on data generated from the replicates. For the basal breast carcinoma xenografts, the numbers of identified proteins among the 10 replicates ranged from 4,771 to 6,190 and the coefficient of variance was 8%; for the luminal breast carcinoma xenografts, the numbers ranged from 4,639 to 5,842 and the coefficient of variance was 7%.
For quantitative analysis, spectral count data from the quality control data set were subjected to quantile normalization 58 using the normalizeQuantiles function in the limma package in Bioconductor, followed by log base 2 transformation. Pairwise Spearman's correlation coefficient was calculated for all sample pairs and the results were plotted in R. Samples from the same group showed a high similarity (Spearman's correlations of 0.85 and 0.88 for W16 and W2, respectively), whereas samples from different groups are clearly different (Spearman's correlation, 0.68) (Extended Data Fig. 5a ). Consistent with this, in the TCGA tumour data set (Supplementary Table 4) , the five duplicate pairs showed an average Spearman's correlation coefficient of 0.81.
In addition to the quantile normalization, other normalization methods commonly used in shotgun proteomics data analysis include global normalization 59 and the NSAF 60 (normalized spectral abundance factor). The quantile normalization makes the distributions of spectral count data from individual samples comparable to each other. The global normalization method makes the total numbers of identified spectra comparable across all samples. The NSAF method normalizes for both protein length and the total number of identified spectra from a sample. We performed all three types of normalization for the quality control data set and log transformation was applied for all normalized data. Among the three normalization methods, NSAF has a clear advantage for comparing abundance level across proteins because it is the only one that considers protein length. However, it is not clear which method is the best for comparing relative abundance of individual proteins among different samples. We compared the three methods on the basis of the intraclass correlation coefficient (ICC) analysis. For each normalization method, we used the icc function in the R package irr to calculate ICCs for individual proteins in the quality control data set. For each protein, the ICC score estimates the correlation between replicated measurements within a group, or the ratio of the between-group variance to the total variance observed for the protein. Our assumption is that better normalization methods should produce higher ICC scores. The analysis was done for the top 1,000, 500 or 100 proteins with the largest variance. The cumulative fraction curves for the ICC scores were plotted in R (Extended Data Fig. 5b ). Each curve shows the cumulative fraction of all proteins in a given normalization method that had an ICC score less than or equal to a given value. The results suggested that quantile normalization generated slightly more consistent quantification than total spectral count normalization, and both methods clearly out-performed the NSAF normalization. Therefore, quantile normalized spectral count data were used in all analyses comparing relative abundance of individual proteins among different samples.
Spectral-count-based quantification is not accurate enough for comparing relative expression of low-abundance proteins. To decide a minimal number of ARTICLE RESEARCH spectral counts to be required for reliable relative comparison, we used the ICC analysis to compare the ICC scores for proteins with different abundance levels. Specifically, we sorted all proteins in the quality control data set based on their total spectral counts and then divided the proteins into 10 bins with equal numbers of proteins. For each bin, we used the icc function to calculate ICCs for individual proteins in the bin. The analysis was done for the top 300, 200 or 100 proteins, with the largest variance in each bin. The cumulative fraction curves for the ICC scores were plotted in R (Extended Data Fig. 5c ). Protein bins with spectral counts less than 1.4 showed clearly lower ICC scores, whereas the ICC score curves started to converge when the average spectral count was greater than 1.4. These data suggest that an average minimum spectral count of 1.4 per sample is required for reliable comparison of relative protein abundance. Applying this cutoff to the TCGA tumour data set identified 4,122 protein groups with a protein-level FDR of 0.47%. The 3,899 corresponding genes were used to compare relative protein abundance across tumour samples. Impact of SNVs on protein expression. All nonsynonymous protein coding SNVs detected from the RNA-seq data were annotated for their existence in dbSNP135, COSMIC64, and previously reported somatic mutations 6 . For each SNV in one of the above three categories, if the SNV-containing gene is included in the 3,899 genes with sufficient spectral count data for quantitative comparison across samples, we quantified the impact of the SNV on protein expression by comparing protein expression level of the gene in the SNV-containing sample with those in samples without the SNV using the formula: Impact score 5 (EXP 2 MEDIAN non-SNV )/MAD non-SNV where EXP is the expression level of the protein in the sample containing the SNV, and MEDIAN non-SNV and MAD non-SNV are the median and MAD (median absolute deviation) of the expression levels of the protein in all samples without the SNV.
The cumulative fraction curves for the impact scores of SNVs in the three categories were plotted in R (Fig. 1d) . Differences between the distributions were evaluated using the Kolmogorov-Smirnov test. A Chi-squared test was also used to directly compare the percentage of high impact variations (absolute impact score greater than 2) for SNVs in different categories (Fig. 1d) . Parallel reaction monitoring analysis. We selected three distinct SAAVs detected in four TCGA samples by the shotgun analysis for further validation by targeted proteomic analyses using parallel reaction monitoring (PRM) 61 , including KRAS(Gly12Asp) in TCGA-AA-3818 and TCGA-AG-A00Y, ANXA11(Ile278Val) in TCGA-AF-3400, SRSF9(Tyr35Phe) in TCGA-AA-A01P. These samples were prepared by the same method as used for shotgun analyses, including basic RPLC fractionation. The samples were re-suspended in 50 ml water containing 2% acetonitrile and 0.1% formic acid containing 12.5 fmol ml 21 each of the 13 C 15 N-isotopically labelled standards for the target variant peptides. All fractions from each sample were analysed separately.
All peptide separations were performed using an Easy nLC-1000 pump and autosampler system (Thermo Fisher Scientific). For each analysis, 2 ml of each sample was injected onto an in-line solid-phase extraction column (100 mm 3 6 cm) packed with ReproSil-Pur C18 AQ 3 mm resin (Dr. Maisch GmbH) and a frit generated with liquid silicate Kasil 1 and washed with 100% Solvent A (0.1% formic acid) at a flow rate of 2 ml min
21
. After a total wash volume of 7 ml, the precolumn was placed in-line with a PicoFrit capillary column (New Objective, 11 cm 3 75 mm) packed with the same resin. The peptides were separated using a linear gradient of 2% to 35% Solvent B (0.1% formic acid in acetonitrile) at a flow rate of 300 nl min 21 over 40 min, followed by an increase to 90% B over 4 min and held at 90% B for 6 min before returning to initial conditions of 2% B.
PRM analyses were performed on a Q-Exactive mass spectrometer (Thermo Fisher Scientific). For ionization, 1,800 V was applied and a 250-uC capillary temperature was used. All basic RPLC fractions from each sample were analysed using an acquisition method that combined a full scan selected ion monitoring (SIM) event followed by 14 PRM scans as triggered by an unscheduled inclusion list containing the target precursor ions representing variant peptides. The SIM scan event was collected using a m/z 380-1,500 mass selection, an Orbitrap resolution of 17,500 (at m/z 200), target automatic gain control (AGC) value of 3 3 10 6 and a maximum injection time of 30 ms. The PRM scan events used an Orbitrap resolution of 17,500, an AGC value of 1 3 10 6 and maximum fill time of 80 ms with an isolation width of 2 m/z. Fragmentation was performed with a normalized collision energy of 27 and MS/MS scan were acquired with a starting mass of m/z 150.
All PRM data analysis was performed using Skyline software 62 . Validation was achieved by comparing the fragment ion ratios and retention times of the endogenous variant peptide to that of the isotopically labelled standard. In addition, the MS/MS spectra of the endogenous, unlabelled and isotope-labelled standards acquired during the PRM analyses were compared to the original MS/MS spectra collected for the same peptides during the shotgun analyses. We successfully confirmed all selected mutations and one example is shown in Extended Data Fig. 4 . Evaluating mRNA-protein correlation. mRNA data. We downloaded the TCGA CRC RNA-seq data from the TCGA portal, which was from Illumina HiSeq 2000 RNA Sequencing Version 2 analysis and normalized by the RSEM algorithm 63 . This included RSEM measurements for 87 samples with matched proteomic data. It has been shown that RSEM is preferred over the popular FPKM 64 (fragments per kilobase (of exon) per million fragments mapped) measure for comparing gene expression across samples. However, our analysis suggested that the RSEM measure is highly correlated with gene length (Extended Data Fig. 6a ) and thus not appropriate for comparing expression of different genes within a sample. Therefore, we used cufflinks 64 to generate FPKM measures. As mentioned above, we were unable to obtain the BAM file for one of the 87 samples, thus only 86 samples had FPKM data. Unlike RSEM, FPKM is independent of gene length (Extended Data Fig. 6a ) Number of overlapping genes in the proteomics and RNA-seq data sets. The proteomics data set for TCGA tumours included a total of 7,211 genes, among which 7,176 genes were included in the RNA-seq data set. The analysis for correlation between steady state mRNA and protein abundance (see below) (Fig. 2a) did not involve the comparison of relative protein abundance for the same gene across samples. For this analysis, all 7,176 genes were included. The analysis for correlation between mRNA and protein variation (Fig. 2b) involved relative protein abundance comparison for the same gene across samples. Our study of the quality control data set suggests that a minimal average spectral count of 1.4 is required for a reliable relative protein abundance comparison. Among the 7,211 genes in the proteomics data set, only 3,899 met this requirement. Moreover, among the 3,899 genes, only 3,764 were included in the RNA-seq data set. Therefore, the 3,764 genes were used in the analysis for correlation between mRNA and protein variation. Correlation between steady state mRNA and protein abundance. To compare the steady state mRNA and protein abundance within individual samples, all mRNA and protein measurements within a sample have to be comparable. Thus, we used the FPKM and NSAF values to estimate mRNA and protein abundance, respectively. For each of the 86 samples, we calculated the Spearman correlation coefficient between FPKM and NSAF measurements for the 7,176 genes. Next, P values corresponding to the coefficients were computed and adjusted by the Benjamini-Hochberg procedure 65 . Significant calls were made based on an adjusted P value cutoff of 0.01. Correlation between mRNA and protein variation. To compare mRNA and protein variations across samples, we focused on the 3,764 genes with both RSEM measurement in RNA-seq data and a minimal spectral count of 1.4 per sample in the proteomics data. The quantile normalized proteomics data were used for this analysis according to the quality control databased method comparison results (Extended Data Fig. 5b ). We first calculated the Spearman correlation coefficient between RSEM and quantile normalized measures for each of 3,764 genes. Then, P values corresponding to the coefficients were computed and adjusted by the Benjamini-Hochberg procedure. Significant calls were made based on an adjusted P value cutoff of 0.01. KEGG enrichment analysis. Based on the Spearman correlation coefficients between RSEM and quantile normalized measurements of the 3,764 genes, we performed KEGG enrichment analysis using the Kolmogorov-Smirnov test. Then, P values were adjusted by the Benjamini-Hochberg procedure and significant calls were made based on an adjusted P value cutoff of 0.05. mRNA-protein correlation versus stability of the molecules. A recent study in a mouse fibroblast cell line suggests a poor correlation between mRNA and protein half-lives 66 . To investigate the relationship between mRNA-protein correlation and the stability of the molecules, we downloaded mRNA and protein half-life data from the mouse study. Only common genes in both our study and the mouse study were included in the analysis. Following the criteria used in the original publication 66 , we defined the top third mRNAs and proteins with the highest halflives as stable mRNAs and proteins and the bottom third with the lowest half-lives as unstable mRNAs and proteins. Accordingly, we separated human genes into four categories based on the mRNA and protein half-lives of their mouse orthologues: stable mRNA-stable protein; stable mRNA-unstable protein, unstable mRNA-stable protein, and unstable mRNA-unstable protein. Distribution of mRNA-protein correlations for genes in each category was plotted in Extended Data Fig. 6b . Correlation difference among the four categories were evaluated based on the Kruskal-Wallis non-parametric ANOVA test, and the difference between the stable mRNA-stable protein, and unstable mRNA-unstable protein groups were calculated based on a two-sided Wilcoxon rank-sum test. Impact of copy number alterations on gene and protein abundance. Univariate analysis. The TCGA CRC gene level CNA data were downloaded from the output of GISTIC2 (ref. 67) in Firehose. The data set was generated on the Affymetrix Genome-Wide Human SNP Array 6.0 array and contained 23,125 genes and 575 samples. The matched CNA, proteomics and RNA-seq measurements from 85 samples were used to study the impact of CNA on gene and protein expression. First, for each of the 23,125 genes in the CNA data, we calculated the Spearman correlation coefficient between CNA measures and mRNA and protein abundance for the 3,764 genes with both RSEM measurements in RNA-seq and a minimal spectral count of 1.4 per sample in proteomics. Then, P values corresponding to the coefficient were corrected using the Benjamini-Hochberg procedure. Significant CNA-mRNA and CNA-protein correlations were identified based on an adjusted P value cutoff of 0.01. Multivariate analysis. In addition to the univariate analysis, we also employed a recently developed statistical tool-regularized multivariate regression for master predictors (remMap) 18 -to jointly model CNAs and mRNA and protein abundance. For this analysis, the level-three segmented DNA copy numbers profiles were downloaded from Firehose (http://gdac.broadinstitute.org, version 20130809). To align the segment data from different samples, we first broke the genome using the union of the break points detected in all tumour samples and filtered the small regions with less than 10 megabase pairs. This resulted in 7,219 regions. Then for each region of each sample, we recorded its copy number based on the inferred DNA copy number of the corresponding segment in the sample, with tail values truncated at 61.5. Owing to the high spatial correlation in DNA copy number profiles, we further condensed these 7,219 regions into 1,586 CNA intervals, which have consistent DNA copy number pattern across all samples, by applying fixed order clustering (FOC) 68 . The copy number for each interval in each sample was then calculated as the mean of the copy number of all regions within the interval. In the end, we normalized the copy number of each CNA interval across all samples to have mean 0 and standard deviation 1.
RNA-seq data and proteomics data were the same as those used in the univariate analysis. For the RNA-seq data, we excluded genes that show interquartile range (IQR) less than the 75% quantile, which resulted in 941 genes. Then we normalized the abundance of each gene across all samples to have mean 0 and standard deviation 1. For the proteomics data, we excluded proteins that show IQR less than the 75% quantile, which resulted in 941 proteins. Then we normalized the abundance of each gene across all samples to have mean 0 and standard deviation 1.
The data matrices of CNV intervals, mRNA abundance and protein abundance obtained as described above were used to fit the remMap model 18 . Specifically, mRNA (or protein) abundances were treated as responses and CNA data were treated as predictors. Non-zero coefficients in the multivariate regression model suggest regulation relationships between the corresponding CNA and mRNA (or protein). The tuning parameters in remMap were selected based on two-dimensional grid research using fivefold cross validation error scores. The optimal tuning parameter was (l 1 , l 2 ) 5 (6, 90) for regression models between mRNA and CNA; and (l 1 , l 2 ) 5 (10, 60) for models between protein and CNA. Regulations between a CNA interval and an mRNA (or protein) were declared if the corresponding coefficients in the regression models from all five models inferred in the cross validation were non-zero.
The results are summarized in Supplementary Tables 6-9 . Five CNA intervals in cytoband regions 11p15.5, 18p12.32-1811.21, 18q21.2-18q23, 20q11.21-20q11.23 and 20q11.23-20q13.33 were detected to be trans hubs for mRNA abundance. And four of these regions on chromosomes 18 and 20 were also detected to be trans hubs for protein abundance. Specifically, the two CNA intervals on chromosome 20q had the highest number of trans regulations for both mRNA and protein abundance (Supplementary Tables 6 and 7) . Reanalysis of HNF4A shRNA knockdown data. HNF4a is a transcription factor with a key role in normal gastrointestinal development 19 and is increasingly being linked to liver and colon cancer 20 . The observations that HNF4A is located in an amplification peak and shows significant CNV-mRNA, CNV-protein and mRNA-protein correlations (Fig. 3c) support its oncogenic role. Consistent with this view, a recent study on 102 human cancer cell lines in the Achilles project found that shRNA knockdown of HNF4A has a relatively stronger negative impact on proliferation and viability of colon cancer cells compared to other cancer cell types 21 . However, there are contradictory reports on whether HNF4a acts as an oncogene 69, 70 or a tumour suppressor gene 71, 72 in CRC. It has been suggested that HNF4a isoforms driven by different promoters may have different roles in colon cancer: promotor 1 (P1) HNF4a acts as a tumour suppressor, whereas the exact role of P2 HNF4a remains to be determined 20, 72 . The P1-and P2-driven isoforms differ by only 16-29 amino acids in their N-terminal domain 20 , and our shotgun proteomics data were not able to distinguish these two types of isoforms (Extended Data Fig. 8a) . However, one of the shRNAs used in the Achilles project specifically targets P1 HNF4a (Extended Data Fig. 8a) . Therefore, we reanalysed data from the Achilles project to compare the effect of different HNF4A-targeting shRNAs on the proliferation of colon cancer cell lines. We also took into consideration the HNF4A amplification status of the cell lines.
Specifically, we downloaded the shRNA knockdown data from the Achilles project website (http://www.broadinstitute.org/software/cprg/?q5node/10). The study had five HNF4A shRNAs: TRCN0000019189, TRCN0000019190, TRCN 0000019191, TRCN0000019192 and TRCN0000019193. A consistency score (C score) for each shRNA that represents the confidence that its observed phenotypic effects are the result of on-target gene suppression is provided on the website based on the ATARiS algorithm, with a higher value representing higher confidence. Based on the C score, the website suggests that only three shRNAs are acceptable: TRCN0000019189, TRCN0000019191 and TRCN0000019193. Therefore, we only included the three shRNAs in our analysis. Amplification data for the cell lines were downloaded from the Cancer Cell Line Encyclopedia (CCLE) project 73 . There were 18 common CRC cell lines in the two projects. For each shRNA, we calculated the Spearman's correlation coefficient between its effect score on the 18 cell lines and the log base 2 transformed copy number values for HNF4A.
As shown in Extended Data Fig. 8b-d , shRNAs simultaneously targeting both P1 and P2 isoforms (TRCN0000019189 and TRCN TRCN0000019191) showed a primarily negative impact on cell proliferation, whereas the P1-specific shRNA TRCN0000019193 showed mixed impacts. Interestingly, a stronger negative impact was associated with increased copy number, both for all shRNAs (P 5 0.01, Spearman's correlation P values for individual shRNAs summarized by the Fisher's combined probability test) and for the P1-specific shRNA (P 5 0.04, Spearman's correlation). These data suggest that the role of HNF4a is not only isoform-specific, but also depends on the status of HNF4A amplification. It is possible that the oncogenic role of HNF4a is primarily related to tumours with HNF4A amplification. Consistently, compared to normal colon samples, significant upregulation of HNF4a was only observed in a specific CRC subtype (Fig. 4d) . Proteomic subtype identification and characterization. Proteomic subtype identification. The normalized protein expression data set of 90 CRC samples was filtered to identify 1,263 proteins that were expressed (that is, with non-zero values) in at least 95% samples and also variably expressed among the 90 samples with a MAD value greater than 0.5. Based on the 1,263 selected proteins, we performed consensus clustering 24 implemented in GenePattern 74 . In consensus clustering, perturbations of the original data are simulated by resampling techniques. Clustering algorithm is applied to each of the perturbed data sets and the consensus among the multiple runs is assessed and summarized in a consensus matrix. Visual inspection of the consensus matrixes, and of the corresponding summary statistics (for example, area under the curve) can help determine the optimal number of clusters as described in the original publication 74 . The parameters used were set as follows: clustering algorithm 5 hierarchical clustering; clustering metrics 5 (1-Pearson correlation) distance and average linkage; n resamplings 5 1,000; proportion of samples and proteins used in each resampling 5 80%; k tested 5 from 2 to 8.
According to the consensus matrices and the empirical cumulative distribution function (CDF) plots shown in Extended Data Fig. 9a , b, k 5 7 led to a clean consensus matrix and no obvious increase in clustering stability was observed going from k 5 7 to k 5 8. Thus, the 90 CRC samples were divided into seven clusters. As it is difficult to interpret the biological meaning of small clusters, only five clusters with more than five samples were kept. Thus, five subtypes were used for the following analysis. Core sample identification. Following ref. 75 , we defined the 'core samples' for each subtype as those with higher similarity to their own class than to any other classes and identified 79 core samples, as indicated by positive silhouette width scores 76 (Extended Data Fig. 9c ). Association with transcriptomic subtypes, methylation subtypes and genomic features. To associate the proteomic subtypes with genomic, epigenomic and clinical features of CRC, we downloaded the somatic mutation matrix (gene by sample) from the cBio cancer genomics portal 77 and obtained other sample information, including mRNA subtype, methylation subtype, hyper-mutation information, MSI information, stage information, cancer type, histological type and tumour site from the Supplementary Information table of TCGA CRC paper 6 . To obtain 18q loss information, we downloaded the CNV data from the Firehose website (http://gdac.broadinstitute. org, version 20130116). The association between each proteomic subtype and each feature was determined using a two-sided Fisher's exact test. The P values were corrected for multiple testing using the Benjamini-Hochberg procedure 65 . The results are summarized in Supplementary Table 11 . Proteomics data set for normal colon samples. Normal colon epithelium biopsies were obtained from screening colonoscopies performed between July 2006 and October 2010 under Vanderbilt University Institutional Review Board (IRB) approval no. 061096. During colonoscopy, multiple pinch biopsies were obtained from both ascending and descending colon and immediately frozen in liquid nitrogen. Biopsies obtained from 30 subjects with completely normal findings during colonoscopy were included in the study. A total of 60 specimens, one from ascending and one from descending colon, were used for proteomic analysis. Samples were processed identically to the colorectal tumour specimens as described ARTICLE RESEARCH above and subjected to MS/MS analysis as described. The data were searched using the three search engines as outlined above. A protein assembly was made for the comparison of the TCGA tumours with the normal samples using IDPicker 3 as described in earlier at 0.2% PSM FDR and a minimum of 2 (distinct) spectra required per protein. The resulting assembly consisted of 6,044 confidently identified protein groups with a protein FDR of 4.1%. This data set was merged with the TCGA tumour data set using IDPicker 3, resulting in a combined tumour-normal proteomic data set of 7,548 protein groups with a protein FDR of 2.7% identified with a grand total of 9,028,208 filtered spectra. These proteins mapped to 7,244 unique genes. The data set were then subjected to quantile normalization, as described in the section on the protein quantification, followed by log transformation. Data from normal ascending and descending colon of the same individual were averaged, resulting in a final data set with 30 normal samples and 90 tumour samples. Only 3,718 quantifiable genes with a minimal average spectral count of 1.4 were included for downstream quantitative comparison (Supplementary Table 13 ). The median effect size in the data set for all 3,718 quantifiable genes is 0.96 as calculated by Cohen's d. According to power analysis, with sample sizes 30 and 90 and an effect size of 0.96, the power for detecting a difference at the significance level of 0.01 is 0.97 using a two-sided t-test. Subtype signature identification and Gene Ontology and network analysis. To identify protein signatures for individual proteomic subtypes, we compared protein expression in each subtype against all remaining subtypes. We also required signature proteins for a subtype to be significantly differently expressed in the subtype compared to normal colon samples. The analysis was based on data in Supplementary Table 13 . A two-sided Wilcoxon rank-sum test was used for differential expression analysis. The P values were corrected for multiple testing using the Benjamini-Hochberg procedure 65 and the statistical significance was determined based on a corrected P value of less than 0.05. Signature proteins are listed in Supplementary Table 14 .
To evaluate the generalizability of the proteomic subtypes and their signature proteins, we performed a leave-one-out cross validation. Specifically, one of the 79 samples was set aside and the remaining 78 samples and the normal samples were used to identify protein signatures and train a nearest shrunken centroid classifier for the proteomic subtypes using the R package pamr 78 . The trained classifier was then applied to the set-aside sample. This was repeated 79 times for all tumour samples and the cross-validation error rate was calculated. We obtained a low error rate of 3.8%, suggesting good generalizability of the proteomic subtypes and their signature proteins.
Gene Ontology enrichment analysis was carried out in WebGestalt 28,79 using the Fisher's exact test with an adjusted P value cutoff of 0.05, and enriched Gene Ontology terms were further analysed using the Gene-Ontology-function algorithm 80 to generate a parsimonious list of enriched terms (Supplementary Table 15 ). Network analysis was performed in NetGestalt 30 using the iRef protein-protein interaction network 81 as a reference network. Using the NetSAM 30 algorithm, NetGestalt derived a linear order of all genes in the iRef network according to the hierarchical organization of the network and identified network modules at different hierarchical levels. As a result, expression data and gene lists can be covisualized in the system as tracks and enriched network modules can be identified and visualized. Enriched network modules were identified based on the Fisher's exact test as implemented in NetGestalt. The Fisher's exact test P values were corrected for multiple testing using the Benjamini-Hochberg procedure 65 and the statistical significance was determined based on an adjusted P value of less than 0.01. Figure 2 | Relaxing the false discovery rate of peptidespectrum match for high-confident proteins increases spectral counts. To increase spectral counts and improve statistical comparisons, we first created a protein assembly that maximized the number of proteins identified (at 0.1% peptide-spectrum match false discovery rate (PSM FDR)) and then relaxed the PSM FDR to 1% exclusively for the set of confidently identified proteins. This strategy led to increased spectral counts from 4,896,831 to 6,299,756, a 29% increase. a, Spectral count plot of all 7,526 confidently identified proteins demonstrates the increase in the absolute number of spectra identified for each protein, but no decrease for any of the proteins. Each dot in the figure represents one of the 7,526 proteins; x axis and y axis represent the spectral counts obtained in the data sets with 0.1% and 1% PSM FDR, respectively, both plotted on a log scale. b, Density plot showing the distribution of PSM FDR scores for all rescued PSMs. Rescued PSMs are of high quality with a median PSM FDR score of less than 0.2%, indicating the maintained integrity of the data set.
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Extended Data Figure 9 | Consensus matrices, the empirical cumulative distribution function plot and core sample identification. a, Consensus matrices of the 90 CRC samples for k 5 2 to k 5 8. The consensus matrices show the robustness of the discovered clusters to sampling variability (resampling 80% samples) for cluster numbers k 5 2 to 8. In each consensus matrix, both the rows and the columns were indexed with the same sample order and samples belonging to the same cluster frequently are adjacent to each other. For each pair of samples, a consensus index, which is the percentage of times they belong to the same cluster during 1,000 runs of the clustering algorithm based on resampling was calculated. The consensus index for each pair of samples was represented by colour gradient from white (0%) to red (100%) in the consensus matrix. b, Cumulative distribution function (CDF) plots corresponding to the consensus matrices for k 5 2 to k 5 8. This plot shows the cumulative distribution of the entries of the consensus matrices within the 0-1 range. Skew towards 0 and 1 indicates good clustering. As k increases, the area under the CDF is hypothesized to increase markedly until k reaches the k true . In this case, 7 was considered as k true because the change of the area under the CDF was close to zero when k increased from 7 to 8. c, Silhouette plot for core sample identification. For each sample (y axis), the silhouette width (x axis) compares its similarity to its assigned class and to any other classes. Samples with higher similarity to their assigned class than to any other classes will get positive silhouette width score and be selected as core samples.
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